论文部分内容阅读
目的探讨c-erbB2癌蛋白在原发乳腺癌组织中的表达情况及其与预后的关系。方法采用免疫组化SP法检测284例原发乳腺癌组织的c-erbB2表达,并用统计学分析其与预后的关系。结果284例原发乳腺癌c-erbB2的阳性表达率为26.8%(76/284),其表达与淋巴结转移数目(P=0.003)密切相关。单因素分析表明,c-erbB2是总生存时间(OS,P=0.002)和无病生存时间(DFS,P=0.024)的重要预后因素;多因素分析表明,c-erbB2是影响OS(P=0.023)的独立预后因素。此外,c-erbB2阳性的肿瘤患者较阴性者更易于发生内脏转移。而对于不同的淋巴结转移和ER状态,c-erbB2也有不同的预后价值。结论c-erbB2是影响原发乳腺癌患者OS的独立因素;在不同的淋巴结转移和ER状态下,其预后价值不同。
Objective To investigate the expression of c-erbB2 oncoprotein in primary breast cancer and its relationship with prognosis. Methods The expression of c-erbB2 in 284 cases of primary breast cancer was detected by immunohistochemical SP method, and its relationship with prognosis was statistically analyzed. Results The positive rate of c-erbB2 in 284 cases of primary breast cancer was 26.8% (76/284). The expression of c-erbB2 was closely related to the number of lymph node metastases (P=0.003). Univariate analysis showed that c-erbB2 was an important prognostic factor for overall survival (OS, P=0.002) and disease-free survival (DFS, P=0.024); multivariate analysis showed that c-erbB2 was affecting OS (P= 0.023) independent prognostic factors. In addition, patients with c-erbB2-positive tumors are more likely to have visceral metastases than those with negative tumors. For different lymph node metastases and ER states, c-erbB2 also has different prognostic value. Conclusion c-erbB2 is an independent factor affecting the OS of primary breast cancer patients. The prognosis value of c-erbB2 is different under different lymph node metastasis and ER status.